Loading...
01/11 07:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows positive elements like high gross margins and improved EBITDA, yet revenue declined YoY. Challenges such as NIH funding delays, China market struggles, and tariff impacts create uncertainties. However, optimistic guidance and product development initiatives provide potential upside. The Q&A reveals cautious optimism but highlights risks like NIH funding delays. Overall, the sentiment is neutral due to balanced positive and negative factors, with no strong catalysts to drive significant stock price movement in the short term.
Revenue $20.6 million for Q3 2025, at the high end of the guidance range but below the $22 million reported in Q3 2024. The decline year-over-year was attributed to lower sales volume.
Gross Margin 58.4% in Q3 2025, compared to 58.1% in Q3 2024 and 56.4% in Q2 2025. The improvement year-over-year and sequentially was due to better absorption of fixed manufacturing overhead costs, operational efficiency, and an improved mix of higher-margin products.
Adjusted EBITDA $2 million in Q3 2025, up from $1.3 million in Q3 2024. The increase was driven by a $1.4 million reduction in operating expenses, which offset the lower revenue.
Operating Expenses Declined by $1.4 million year-over-year in Q3 2025 due to actions such as moving to one U.S. ERP system, streamlining the SG&A organization, and reprioritizing NPI projects.
Cash Flow from Operations $6.8 million year-to-date in 2025, compared to negative $0.3 million in the same period in 2024. The improvement was driven by better working capital management and reduced operating expenses.
Net Debt $27.5 million as of Q3 2025, down from $33.8 million at year-end 2024. The reduction was due to quarterly principal payments and improved operating cash flow.
Americas Revenue Decreased by 4.4% year-over-year in Q3 2025 but increased sequentially by 3.6%. The year-over-year decline was attributed to lower sales in certain product lines.
Europe Revenue Flat year-over-year in Q3 2025 and increased sequentially by 0.3%. The sequential increase was driven by stronger preclinical academic shipments.
China Revenue Decreased by 19.6% year-over-year in Q3 2025 and 6.3% sequentially. The decline was attributed to ongoing tariff disruptions, though recent trade developments are expected to improve future performance.
SoHo Telemetry rollout: Expanded into additional key accounts with increased recurring consumable demand.
Biochrom amino acid analyzer: Continues to perform well, on pace to exceed last year's consumable revenue.
Incub8 Multiwell System: Launched as a new smart microelectrode array platform for real-time monitoring in organoid and cell culture workflows. Initial customer response positive with first orders and shipments completed.
Mesh MEA organoid platform: Adoption continues to build momentum, supported by regulatory initiatives promoting new methodologies.
Distribution agreement with Fisher Scientific: Expanded to broaden access to Harvard Bioscience products across North America, enhancing visibility in academic and pharmaceutical research markets.
European market: Strong uptick in order volume contributing to increased backlog.
China market: Orders flat sequentially, but optimism for recovery due to recent trade developments.
Revenue: Achieved $20.6 million, at the high end of guidance, with gross margin of 58.4% exceeding expectations.
Cost structure: Lean structure maintained, with $1.4 million reduction in operating expenses year-over-year.
Cash flow: Generated $1.1 million in positive operating cash flow in Q3, with year-to-date cash flow at $6.8 million.
Debt reduction: Net debt reduced by over $6 million from year-end 2024 to $27.5 million.
Capital structure: Progress made on refinancing or repayment of existing credit agreement, expected to complete in Q4.
NIH funding: Monitoring potential impact of U.S. government shutdown on funding distribution.
NIH funding uncertainty: The ongoing government shutdown may impact the timing of NIH funding distribution, which could affect the company's revenue and operations.
China market performance: Revenue in China was down sequentially by 6.3% and year-over-year by 19.6%, indicating challenges in this key market.
Tariff disruptions: Although there is optimism about the reduction of tariff disruptions, past issues have impacted revenue in China and could pose risks if not fully resolved.
Credit facility refinancing: The company is in the process of refinancing or repaying its existing credit agreement, which introduces financial uncertainty until resolved.
Revenue decline in Americas: Revenue in the Americas decreased by 4.4% year-over-year, reflecting challenges in this region.
APAC revenue decline: Revenue in the Asia Pacific region, excluding China, showed improvement, but overall APAC revenue declined year-over-year, indicating broader regional challenges.
Cellular and molecular sales decline: Cellular and molecular sales in Europe and APAC decreased year-over-year by 13% and sequentially by 0.7%, respectively, highlighting product-specific challenges.
Revenue Expectations: Guidance for Q4 revenue is projected to be in the range of $22.5 million to $24.5 million, with the high end reflecting flat revenue compared to the prior year. The lower end accounts for potential risks from a prolonged U.S. government shutdown.
Gross Margin Projections: Gross margin for Q4 is expected to range between 58% and 60%, supported by higher volume and improved demand.
Order Growth and Backlog: Mid-single-digit order growth was achieved in Q3 year-over-year, with four consecutive months of year-on-year growth. The company has its strongest backlog since Q1 2023, supporting confidence in Q4 performance.
Capital Structure and Debt Refinancing: The company is on track to complete refinancing or repayment of its existing credit agreement in Q4, with multiple proposals under review. Progress has been made in strengthening the balance sheet.
Market Trends and Regional Performance: Optimism for increased activity in China following recent trade developments. Strong uptick in order volume in Europe contributing to increased backlog heading into Q4.
NIH Funding and Government Shutdown Impact: Monitoring the potential impact of a U.S. government shutdown on NIH funding distribution, which could affect timing and revenue.
The selected topic was not discussed during the call.
The earnings call reflects a positive sentiment with strong financial performance, including increased EBITDA, net profit, and EPS. Despite some uncertainties in CapEx and costs, the company shows confidence in resolving issues and improving production. The anticipated strong Q4 and optimistic 2026 outlook, alongside potential cost reductions and share buybacks, support a positive stock price movement.
The earnings call presents a mixed picture. Financial performance shows positive elements like high gross margins and improved EBITDA, yet revenue declined YoY. Challenges such as NIH funding delays, China market struggles, and tariff impacts create uncertainties. However, optimistic guidance and product development initiatives provide potential upside. The Q&A reveals cautious optimism but highlights risks like NIH funding delays. Overall, the sentiment is neutral due to balanced positive and negative factors, with no strong catalysts to drive significant stock price movement in the short term.
Despite some positive elements like cost reduction and improved cash flow, the overall sentiment is negative due to the revenue decline, gross margin pressure, debt risks, and macroeconomic uncertainties, including tariffs and NIH funding delays. The Q&A section highlighted concerns about debt refinancing and unclear guidance on NIH budget impacts. Given these factors, along with the lack of a clear positive catalyst, the stock price is likely to experience a negative movement in the next two weeks.
The earnings call reveals several negative indicators: a significant revenue decline, a $48 million goodwill impairment, and decreased margins. Despite cost reduction efforts, challenges in sales due to budget uncertainties and tariffs persist. While there is interest in new products, the impact of NIH funding cuts and unclear refinancing terms add to the uncertainty. The lack of a share repurchase program further dampens sentiment. These factors suggest a negative stock price reaction, potentially in the -2% to -8% range.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
